Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-45779 versus Xolair in chronic spontaneous urticaria despite H1 antihistamines
2021-001796-17Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab biosimilar SYN008 and omalizumab in chronic idiopathic urticaria (CIU) (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Change from baseline in weekly itch severity score at Week 12 and Relative potency based on itch severity score. Started Aug 2021; status: completed.
02
Drugs
omalizumab biosimilar SYN008omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2021-001796-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001796-17.